Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

121. Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Fibrinolysis for patients with intermediate-risk pulmonary embolism. BACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS: In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury (...) patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). CONCLUSIONS: In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006

NEJM2014

123. Timely diagnosis of pulmonary artery tumor embolism by ultrasound-guided transbronchial needle aspiration

Timely diagnosis of pulmonary artery tumor embolism by ultrasound-guided transbronchial needle aspiration 26766998 2016 01 15 2018 11 13 1759-7706 5 2 2014 Mar Thoracic cancer Thorac Cancer Timely diagnosis of pulmonary artery tumor embolism by ultrasound-guided transbronchial needle aspiration. 184-7 10.1111/1759-7714.12062 Pulmonary artery tumor embolism (PATE) is a rare disease without an established diagnostic method. In an autopsy series, however, the incidence of PATE was relatively high (...) , between 3% and 26% in patients with a solid tumor. Here we report a case of a patient with a massive PATE from hepatocellular carcinoma diagnosed safely and promptly by endobronchial ultrasound-guided transbronchial needle aspiration. Lee Seung Jun SJ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gyeongsang National University College of Medicine Jinju, Korea. Lee Jinwoo J Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul

Thoracic cancer2014 Full Text: Link to full Text with Trip Pro

124. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation

CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation 24384101 2014 01 03 2014 02 24 2014 01 03 1555-7162 127 1 2014 Jan The American journal of medicine Am. J. Med. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation. 45-52 10.1016/j.amjmed.2013.10.004 S0002-9343(13)00871-1 The risk stratification score, which includes Congestive heart failure, Hypertension, Age ≥ 75 (...) [doubled], Diabetes, Stroke [doubled]- Vascular disease, Age 65-74, and Sex category [female] (CHA2DS2-VASc), is used to predict stroke in atrial fibrillation. However, whether high CHA2DS2-VASc score carries a higher risk of pulmonary embolism remains unknown. We aimed to investigate the association between the severity of CHA2DS2-VASc score and the incidence of pulmonary embolism. A total of 73,541 adults with atrial fibrillation diagnosed before January 1, 2012, and no history of pulmonary embolism

EvidenceUpdates2014

125. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism (...) : a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

Health Technology Assessment (HTA) Database.2014

127. Thrombolytics for Submassive Pulmonary Embolism

Thrombolytics for Submassive Pulmonary Embolism Emergency Medicine > Journal Club > Archive > September 2014 Toggle navigation September 2014 Thrombolytics for Submassive Pulmonary Embolism Vignette You are working a day shift in your ED when you meet a generally healthy 55 year old male who acutely developed chest pain and shortness of breath at home. He tells you that he underwent an orthopedic procedure 10 days prior. He is tachycardic and has an oxygen saturation of 94% on room air. You (...) order an EKG, which demonstrates an S1Q3T3 pattern and a troponin level which is very mildly elevated at 0.12. You think to yourself, “I’ve got this diagnosis” and order a PE protocol CT which identifies bilateral acute pulmonary emboli with a significant clot burden as well as dilation of the right ventricle. A bedside cardiac ultrasound was suggestive of right ventricular dilatation, so you send the patient to the Cardiac Diagnostic Lab for a formal ECHO, which reveals a markedly dilated right

Washington University Emergency Medicine Journal Club2014

128. Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Fibrinolysis for patients with intermediate-risk pulmonary embolism. 24716681 2014 04 10 2014 04 18 2016 11 25 1533-4406 370 15 2014 Apr 10 The New England journal of medicine N. Engl. J. Med. Fibrinolysis for patients with intermediate-risk pulmonary embolism. 1402-11 10.1056/NEJMoa1302097 The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin (...) in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. Of 1006

NEJM2014

129. Imaging for the Diagnosis of Pulmonary Embolism in Pregnant Women

Imaging for the Diagnosis of Pulmonary Embolism in Pregnant Women BestBets: Imaging for the Diagnosis of Pulmonary Embolism in Pregnant Women Imaging for the Diagnosis of Pulmonary Embolism in Pregnant Women Report By: Simon Bordeleau - Emergency medicine PGY-4 Institution: Laval University, Quebec, Canada Date Submitted: 21st December 2012 Date Completed: 17th April 2013 Last Modified: 17th April 2013 Status: Green (complete) Three Part Question In [Pregnancy with pulmonary embolism (...) ], is [Computed-Tomographic pulmonary angiography better than Ventilation (V) �Perfusion (Q) scintigraphy] for [detection of pulmonary embolism]? Clinical Scenario A 27-year-old female presents to the emergency department with shortness of breath. She is 26 weeks pregnant. The lower limbs Doppler ultrasound is negative. You must perform another diagnostic test to eliminate a pulmonary embolism. You wonder which test is the most appropriate for this patient: a Computed-Tomographic pulmonary angiography

BestBETS2013

130. Rivaroxaban (Xarelto) - treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults

Rivaroxaban (Xarelto) - treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults

Scottish Medicines Consortium2013

131. Changes in PESI scores predict mortality in intermediate-risk patients with acute pulmonary embolism

Changes in PESI scores predict mortality in intermediate-risk patients with acute pulmonary embolism 22743671 2013 02 01 2013 07 30 2013 02 01 1399-3003 41 2 2013 Feb The European respiratory journal Eur. Respir. J. Changes in PESI scores predict mortality in intermediate-risk patients with acute pulmonary embolism. 354-9 10.1183/09031936.00225011 Although the Pulmonary Embolism Severity Index (PESI) accurately identifies 35% of patients with acute pulmonary embolism (PE) as being low risk (...) , some patients deemed high risk by the PESI on admission might be treated safely in the outpatient environment. This retrospective cohort study included a total of 304 consecutive patients with acute PE, classified at the time of hospital admission into PESI class III. The PESI was recalculated 48 h after admission (PESI(48)) and each patient reclassified into the corresponding risk category. The primary outcome of the study was all-cause mortality between day 2 and day 30 after PE diagnosis. 26

EvidenceUpdates2013

132. Submassive pulmonary embolism.

Submassive pulmonary embolism. The US Surgeon General estimates that 100,000 to 180,000 deaths occur annually from acute pulmonary embolism (PE) in the United States. The case of Ms A, a 60-year-old woman with acute PE and right ventricular dysfunction (submassive PE), illustrates the clinical challenge of identifying this high-risk patient population and determining when more aggressive immediate therapy should be pursued in addition to standard anticoagulation. The clinical examination (...) , electrocardiogram, cardiac biomarkers, chest computed tomography, and echocardiography can be used to risk stratify patients with acute PE. Current options for more aggressive intervention in the treatment of patients with acute PE who are at increased risk of an adverse clinical course include systemic fibrinolysis, pharmacomechanical catheter-directed therapy, surgical pulmonary embolectomy, and inferior vena cava filter insertion. Determination of the optimal duration of anticoagulation and lifestyle

JAMA2013

133. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | Guidance and guidelines | NICE Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Technology appraisal guidance [TA287] Published date: 26 June 2013 Share Save Guidance on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further (...) deep vein thrombosis or pulmonary embolism in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected

National Institute for Health and Clinical Excellence - Technology Appraisals2013

134. Cohort study: Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism

Cohort study: Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism Article Text Diagnosis Cohort study Pretest probability assessment combined

Evidence-Based Medicine (Requires free registration)2013

135. Cohort: Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism

Cohort: Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism Article Text Online articles Cohort Thrombolytic therapy with or without

Evidence-Based Medicine (Requires free registration)2013

136. Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Article Text Therapeutics Randomised controlled trial Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non

Evidence-Based Medicine (Requires free registration)2013

137. Moderate Pulmonary Embolism Treated With Thrombolysis (from the MOPETT Trial)

Moderate Pulmonary Embolism Treated With Thrombolysis (from the MOPETT Trial) 23102885 2013 01 07 2013 02 26 2013 08 05 1879-1913 111 2 2013 Jan 15 The American journal of cardiology Am. J. Cardiol. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). 273-7 10.1016/j.amjcard.2012.09.027 S0002-9149(12)02205-9 The role of low-dose thrombolysis in the reduction of pulmonary artery pressure in moderate pulmonary embolism (PE) has not been investigated. Because the lungs (...) are very sensitive to thrombolysis, we postulated that effective and safe thrombolysis might be achieved by a lower dose of tissue plasminogen activator. The purpose of the present study was to evaluate the role of this "safe dose" thrombolysis in the reduction of pulmonary artery pressure in moderate PE. During a 22-month period, 121 patients with moderate PE were randomized to receive a "safe dose" of tissue plasminogen activator plus anticoagulation (thrombolysis group [TG], n = 61 patients

EvidenceUpdates2013

138. Cardiovascular Risk Assessment of Pulmonary Embolism With the GRACE Risk Score

Cardiovascular Risk Assessment of Pulmonary Embolism With the GRACE Risk Score 23168283 2013 01 15 2013 03 05 2013 01 15 1879-1913 111 3 2013 Feb 01 The American journal of cardiology Am. J. Cardiol. Cardiovascular risk assessment of pulmonary embolism with the GRACE risk score. 425-31 10.1016/j.amjcard.2012.10.020 S0002-9149(12)02301-6 Despite the existence of several risk scores, the accurate prediction of the prognosis in pulmonary embolism (PE) remains a challenge. The Global Registry (...) of Acute Coronary Events (GRACE) risk score has a high diagnostic performance for adverse outcomes in acute coronary syndrome. We aimed to assess the applicability and extend the use of the GRACE risk score to PE. A case-control study of 206 consecutive patients admitted with PE was performed. The GRACE, Geneva, Simplified Pulmonary Embolism Severity Index, Shock Index, and European Society of Cardiology risk scores were tested for the prediction of the primary end point: all-cause 30-day mortality

EvidenceUpdates2013

139. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism

Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism 23103660 2013 03 04 2013 08 19 2013 03 04 1522-9645 34 9 2013 Mar European heart journal Eur. Heart J. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism. 693-701 10.1093/eurheartj/ehs365 We evaluated prognostic value at 6 months of residual pulmonary (...) vascular obstruction (RPVO) measured before discharge in patients with intermediate- or high-risk pulmonary embolism (PE). Prospective registry including 416 consecutive patients with intermediate- or high-risk PE who survived the acute phase. Patients with previous cardiopulmonary disease were excluded. Perfusion lung scans were performed within 6-8 days after the onset of treatment. Residual pulmonary vascular obstruction was graded as the proportion of the lung not perfused. Primary objective

EvidenceUpdates2012

140. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study.

Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. OBJECTIVE: To validate the use of the Wells clinical decision rule combined with a point of care D-dimer test to safely exclude pulmonary embolism in primary care. DESIGN: Prospective cohort study. SETTING: Primary care across three different regions of the Netherlands (Amsterdam, Maastricht, and Utrecht). PARTICIPANTS: 598 adults with suspected pulmonary embolism (...) in primary care. INTERVENTIONS: Doctors scored patients according to the seven variables of the Wells rule and carried out a qualitative point of care D-dimer test. All patients were referred to secondary care and diagnosed according to local protocols. Pulmonary embolism was confirmed or refuted on the basis of a composite reference standard, including spiral computed tomography and three months' follow-up. MAIN OUTCOME MEASURES: Diagnostic accuracy (sensitivity and specificity), proportion of patients

BMJ2012 Full Text: Link to full Text with Trip Pro